Austin Bach, DO
Pediatric Ophthalmology and Strabismus Specialist · Hollywood, FLNPI 1659706588
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.5%), speaking fees and gifts — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Amgen at 29.3% of the total. Reporting peaked in 2022 at $3,042 and has fallen 50.1% since, to $1,517 in 2025.
Across 229 payments — averaging $50.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Santen Inc.$2K
- Eyevance Pharmaceuticals LLC$2K
- Bausch & Lomb Americas Inc.$627
- Coopervision Inc.$421
- Kala Pharmaceuticals, Inc.$393
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$4,90642%
- Food & beverage$6,69658%
- Gifts$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$2,412
- Verkazia$2,000
- Zerviate$1,348
- INFUSE$488
- ACTHAR$260
- MiSight Contact Lens$121
- OPMI Lumera$110
- MyDay Contact Lens$104
- Flarex$100
How this compares
Too few pediatric ophthalmology and strabismus specialist providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 184 | $198,973 |
| XiidraLifitegrast | 71 | $80,437 |
| VevyeCyclosporine | 22 | $16,910 |
| Cyclosporine | 27 | $12,938 |
| LumiganBimatoprost | 26 | $10,857 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $8,544 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 126 | $4,662 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $3,301 |
| Prednisolone Acetate | 90 | $3,182 |
| Loteprednol Etabonate | 29 | $3,177 |
| FlarexFluorometholone Acetate | 17 | $2,128 |
| Brimonidine Tartrate | 30 | $1,786 |
| Latanoprost | 197 | $1,733 |
| Ketorolac Tromethamine | 55 | $1,326 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $392 | $209,831210 claims |
| Bausch & Lomb Americas Inc.Xiidra | $627 | $80,43771 claims |
| Harrow Eye, LLCVevye | $94 | $16,91022 claims |
| AlconSimbrinza | $281 | $3,30116 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $116 | $3,17729 claims |
| Eyevance Pharmaceuticals LLCFlarex | $1,628 | $2,12817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric ophthalmology and strabismus specialist providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other pediatric ophthalmology and strabismus specialist in Hollywood
- Dawn DussPonte Vedra Beach$9K
- Robert GoldMaitland$3K
- Louis BlumenfeldMaitland$2K
- Mariana Abi KaramMiami$2K
- Vikisha HazariwalaMaitland$1K
- Scott SilvermanBradenton$908
- Megha PansaraTampa$310
- Tiffany KrugerCrestview$246
- Robert HeredMaitland$211
- Nehemiah SpencerMiami$184
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.